| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 70 | 7.1x | 17.8x | Top tier | |
Growth | 90 | 19.8% | 7.1% | Top tier | |
Quality | 92 | 55.2% | 4.5% | Top tier | |
Safety | 91 | — | 2.6x | Top tier | |
Capital Return | 74 | — | 2.12% | Top tier | |
Momentum | 68 | 25.1% | 2.9% | Top tier | |
Sentiment | 37 | 4 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Aurinia Pharmaceuticals is a biopharmaceutical company whose commercial operations focus on LUPKYNIS for the treatment of lupus nephritis, while developing aritinercept for autoimmune diseases. The revenue model relies heavily on LUPKYNIS sales; in fiscal year 2025, its net sales reached $271.3 million out of total revenue of $283.1 million, or approximately 95.8%, and product sales grew 25% compared with fiscal year 2024.
In Q2 of fiscal year 2026, Aurinia reported revenue of $83.2 million and gross profit of $76.7 million, equivalent to a gross margin of approximately 92.2%, along with net income of $37.4 million, a net margin of approximately 45.0%, and earnings per share of $0.28. Compared with Q1 of fiscal year 2026, revenue increased from $77.7 million by approximately 7.1%, and net income increased from $34.4 million by approximately 8.7%.
Fiscal year 2025 revenue reached approximately $283.1 million, up 20%, or 26% excluding a nonrecurring $10 million milestone payment included in fiscal year 2024. Net income reached $287.2 million, but it included a $173 million tax benefit arising primarily from the release of a deferred tax asset valuation allowance; therefore, pretax income of $114.2 million was a more accurate indicator of operating improvement than the accounting-driven surge in net profit.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” and the average price target is $16, with the highest and lowest targets identical at the same level; therefore, the target range provides no dispersion that can be used to gauge differences in opinion. The $16 target lies between the low and high of the 52-week range of $10.34–$19.25, approximately 16.9% below the high and approximately 54.7% above the low, while no valid price-to-earnings ratio is available for comparison despite fiscal year 2025 net income being inflated by a $173 million tax benefit.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
LUPKYNIS is the company's primary commercial driver in the treatment of lupus nephritis. Its net sales reached $271.3 million in fiscal year 2025, up 25%, and represented approximately 95.8% of total revenue of $283.1 million. In Q4 of fiscal year 2025, product sales reached $74.2 million out of total revenue of $77.1 million.
Revenue reached $83.2 million, compared with $77.7 million in Q1 of fiscal year 2026, representing a sequential increase of approximately 7.1%. Gross profit reached $76.7 million, equivalent to a gross margin of approximately 92.2%. Net income was $37.4 million and earnings per share were $0.28, compared with net income of $34.4 million and earnings per share of $0.25 in the previous quarter.
Management expects total revenue of between $315 million and $325 million in fiscal year 2026, equivalent to growth of between 11% and 15% from fiscal year 2025. It expects LUPKYNIS net sales of between $305 million and $315 million, representing growth of between 12% and 16%. This means continued growth, but at a slower pace than LUPKYNIS's 25% sales growth in fiscal year 2025.
Management said that the pivotal LUPKYNIS trial showed a 50% reduction in proteinuria within one month of starting treatment. Most response objectives associated with the primary endpoint were also achieved within 6 months, despite the study being designed to measure the benefit at 12 months. The company links this speed to guidelines for early diagnosis and intensive treatment, which also recommend continuing treatment for between 3 and 5 years.
Aritinercept represents an effort to expand Aurinia's portfolio beyond its substantial commercial reliance on LUPKYNIS. It is a dual inhibitor of BAFF and APRIL, and the Phase 1 single ascending dose study showed strong and sustained reductions in immunoglobulin, supporting the possibility of once-monthly dosing. The company began a study in one autoimmune disease, and its program announced on February 26, 2026 included beginning a study in an additional disease during the first half of fiscal year 2026.
Net income reached $287.2 million and diluted earnings per share reached $2.07 in fiscal year 2025. However, the results included a $173 million tax benefit, arising primarily from the release of a valuation allowance on deferred tax assets that the company expects to utilize. Therefore, pretax income of $114.2 million and operating cash flow of $135.7 million were measures more closely related to the operating and cash performance of that fiscal year.
